TABLE 1.
Clinical characteristics of the participant
| Characteristics | Endometrial cancer | Endometrial hyperplasia group | Controls group | P |
|---|---|---|---|---|
| Number | 144 | 103 | 80 | |
| Age (y) | 46.33 ± 12.97 | 45.02 ± 10.88 | 44.96 ± 7.53 | .441 |
| W, ×109/L | 6.80 ± 2.21 | 6.67 ± 2.08 | 6.72 ± 2.33 | .257 |
| N, ×109/L | 4.56 ± 1.82 | 4.46 ± 1.77 | 4.62 ± 1.97 | .185 |
| L, ×109/L | 1.83 ± 0.92 | 1.68 ± 0.83 | 1.75 ± 0.84 | .113 |
| Hb, g/L | 102.31 ± 24.62 a | 127.28 ± 18.91 | 131.02 ± 16.22 c | <.001 |
| RDW, % | 15.06 ± 2.30 a | 14.17 ± 2.27 b | 12.76 ± 1.07 c | <.001 |
| PLT, ×1012/L | 232 ± 98.33 | 241 ± 102.36 | 224 ± 95.23 | .174 |
| MPV; (fl) | 12.01 ± 2.68 a | 11.51 ± 2.22 b | 9.58 ± 1.84 c | <.001 |
| PDW, % | 17.02 ± 3.21 | 16.88 ± 2.89 b | 15.89 ± 1.46 c | <.001 |
| CA125; U/mL | 39.06 ± 33.94 a | 32.87 ± 10.77 b | 17.50 ± 8.35 c | <.001 |
P‐values were calculated by one‐way ANOVA tests.
Abbreviations: CA125, cancer antigen 125; Hb, hemoglobin; L, absolute lymphocyte count; MPV, mean platelet volume; N, absolute neutrophil count; PDW, platelet distribution width; PLT, blood platelet count; RDW, red cell distribution width; W, white blood cell count.
a
Shows a significant difference (P < .05) between endometrial cancer group and endometrial hyperplasia group (Tukey's test).
b
Shows a significant difference (P < .05) between endometrial hyperplasia group and controls group (Tukey's test).
c
Shows a significant difference (P < .05) between endometrial cancer group and controls group (Tukey's test).